Cargando…

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases

C-X-C Motif Chemokine Receptor 4 (CXCR4) is part of the human chemokine system and involved in progression and metastasis in renal cell carcinoma (RCC). However, the role of CXCR4 protein expression in RCC remains controversial. In particular, data regarding the subcellular distribution of CXCR4 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maas, Moritz, Kurcz, Aymone, Hennenlotter, Jörg, Scharpf, Marcus, Fend, Falko, Walz, Simon, Stühler, Viktoria, Todenhöfer, Tilman, Stenzl, Arnulf, Bedke, Jens, Rausch, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048828/ https://www.ncbi.nlm.nih.gov/pubmed/36982302 http://dx.doi.org/10.3390/ijms24065227

Ejemplares similares

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
por: Stühler, Viktoria, et al.
Publicado: (2022)

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma
por: Sauter-Meyerhoff, Carolin, et al.
Publicado: (2021)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Real world data on IO-based therapy for metastatic renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2022)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
por: Kruck, Stephan, et al.
Publicado: (2013)

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review
por: Walz, Simon, et al.
Publicado: (2020)

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
por: Winter, Stefan, et al.
Publicado: (2016)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
por: Todenhöfer, Tilman, et al.
Publicado: (2012)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
por: Wei, Yi, et al.
Publicado: (2022)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Androgen receptor overexpression in prostate cancer in type 2 diabetes
por: Lutz, Stefan Zoltán, et al.
Publicado: (2017)

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study
por: Horstmann, Marcus, et al.
Publicado: (2014)

Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer
por: Harland, Niklas, et al.
Publicado: (2021)

Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria
por: Hennenlotter, Joerg, et al.
Publicado: (2011)

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer
por: Heni, Martin, et al.
Publicado: (2012)

Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes
por: Franko, Andras, et al.
Publicado: (2020)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2014)

Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB
por: Todenhöfer, Tilman, et al.
Publicado: (2021)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
por: Aicher, Wilhelm K., et al.
Publicado: (2021)

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
por: Bedke, Jens, et al.
Publicado: (2013)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes
por: Sittig, Simone P, et al.
Publicado: (2013)

Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation
por: Stickel, Juliane S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ksudldmo133htstr01a1bpr6la